Vancouver, British Columbia, April 4, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), An evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapies, and outsourced research, its board of directors is pleased to welcome Najla Guthrie as its new CEO (). “CEO”) Effective March 31, 2022. Guthrie has been appointed to lead the development of an evolved competitive strategy through the company’s new mission and vision. Previously announced achievements by KKG Science Inc., a wholly owned subsidiary of Wellbeing (“KGK“) And IRP Health (“IRP”), Guthrie’s tenure and well-being’s new leader.
Guthrie has been President and Chief Executive Officer of KGK since 1997 and has recently held the title of Chief Executive Officer of Wellbeing. Over the years, Najla has grown KGK into a leading North American commissioned research institute, providing high-quality clinical research trials focused on the dietary supplement, cannabis, and emerging psychedelic industries. Guthrie has been instrumental in publishing more than 50 papers in peer-reviewed journals and has made numerous presentations at both national and international levels. Najla fits well into her new role as Wellbeing CEO and is highly regarded in the research, science, and leadership communities.
As a summary of our recent achievements, KGK was selected by Lophos Pharmaceuticals Inc. for new research to assess the path to the market for sustainable growing peyote-derived natural health products. Well-being has also begun a single-arm open-label trial in patients with post-traumatic stress disorders who are undergoing their own physiotherapy program at the IRP Clinic. The IRP recently implemented an innovative rejuvenation therapy program officially approved by Canadian veterans as an interdisciplinary clinic outpatient program at three locations. Finally, the Victoria Wellness-related inpatient ketamine integrated therapy experience program continues to improve the patient’s quality of life through IV ketamine treatment.
Regarding our intention to acquire a listing through an initial public offering on the US senior stock exchange, we have completed the GAAP-based audit in 2020 and completed the audit in 2021. Well-being has also made significant progress in completing the required filing requirements and continues to work with advisors to achieve this significant capital market initiative.
“I am honored to be welcomed as the new CEO of Wellbeing. I am grateful to Adam Deffett, his hard work as Interim CEO and his active contribution to Wellbeing since last year. We feel ready to lead the company, are optimistic about the future of the company, and can truly make a difference in the mental health industry to mitigate the crisis we are facing. ” Well-being CEO Najira Guthrie said. “We are proud of the achievements both KGK and IRP have announced over the past few months. They reaffirm the value of both businesses as part of the overall well-being and third digital therapy. We are co-emphasizing it as a strategic pillar and look forward to having a positive and lasting impact on mental health illness views and treatments, “Guthrie added.
About KGK Science
Founded in 1997, KGK is a leading North American commissioned research institute based in London, Ontario, providing high-quality clinical research trials focused primarily on dietary supplements and emerging healthcare products. I am. The business has helped hundreds of companies with custom-designed clinical trials and advocated empirical strategies to move their products to the global market. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services, and consulting services. To date, the business has produced an estimated 150 publications, conducted more than 400 clinical trials with more than 40 indications, attracted 25,000 participants to the database, and collected 10 million data points. ..
About Wellbeing Digital Science
Wellbeing Digital Sciences Inc. is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapies, and outsourced research. Its mission is supported through a network of North American clinics that provide patients with ketamine-assisted therapies and other types of treatment, and outsourced research institutes that provide clinical trial services to clients seeking drug development. In essence, the company exists to make breakthrough treatments more accessible and provide patients with a transformational experience.
on behalf of:
WELLBEING DIGITAL SCIENCE SINC.
Najla Guthrie, CEO
For more information, please contact:
Nick Kuzyk, Investor Relations
Notice of future prospects:
This news release contains forward-looking statements, including but not limited to statements about our business, assets or investments, and other statements that are not historical facts. Readers should be careful not to place excessive reliance on forward-looking statements. There is no guarantee that plans, intentions, or expectations will arise based on them. By its very nature, forward-looking statements include general and specific known and unknown risks and uncertainties that contribute to the possibility that forecasts, forecasts, forecasts, and other forward-looking statements do not occur. Contains a number of assumptions, including. Future performance and results differ materially from estimates or forecasts of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, investor interest in general economic conditions, especially capital markets, our business and outlook.
Forward-looking statements contained in this news release were made as of the date of this news release. Except as required by law, we intend to update or revise our forward-looking statements as a result of new information, future events, etc., except as required by applicable securities law. It shall be abandoned and shall not be obliged. In addition, the Company shall not be obliged to comment on the expectations or remarks of third parties regarding the above matters.
Source: WELLBEING DIGITAL SCIENCE SINC.
CBJ News Maker
Wellbeing Digital Sciences welcomes Najla Guthrie as Chief Executive Officer of the Canadian Business Journal
Source link Wellbeing Digital Sciences welcomes Najla Guthrie as Chief Executive Officer of the Canadian Business Journal